Loading…
Thorough QT Studies: Questions and Quandaries
The International Conference on Harmonisation E14 Guidance was successful in largely standardizing the conduct of the so-called thorough QT/QTc studies (TQTS). Nevertheless, there is still a spectrum of frequently encountered problems with details of design, conduct and interpretation of TQTS. Sever...
Saved in:
Published in: | Drug safety 2010, Vol.33 (1), p.1-14 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c465t-19cd53c474417a54cb2d498d80abbee49268fac2293334b54e88774cde7ff1ff3 |
container_end_page | 14 |
container_issue | 1 |
container_start_page | 1 |
container_title | Drug safety |
container_volume | 33 |
creator | Malik, Marek Garnett, Christine E. Zhang, Joanne |
description | The International Conference on Harmonisation E14 Guidance was successful in largely standardizing the conduct of the so-called thorough QT/QTc studies (TQTS). Nevertheless, there is still a spectrum of frequently encountered problems with details of design, conduct and interpretation of TQTS. Several of these challenges are reviewed here, starting with explaining that the TQTS goal is only to identify drugs for which the proarrhythmic risk might be considered excluded for the purposes of regulatory benefit-risk assessment. Suggestions are made on how to categorize and quantify or exclude proarrhythmic risk if the TQTS is positive. There is a conceptual need for TQTS, and this is discussed, together with reasons why restricted clinical registries cannot prove the absence of proarrhythmic liability of any drug.
Appropriate drug doses investigated in TQTS should be derived from the maximum clinically tolerable dose rather than from the known or expected therapeutic dose. With the help of concentration-QTc modelling, the standard therapeutic dose can be omitted from TQTS, especially if the study is expected to be negative. Conditions for single-dose TQTS acceptability are reviewed. The role of the so-called positive control is assessed, contrasting the role of a same-class comparator for the investigated drug. A single 400 mg dose of moxifloxacin is advocated as the present ‘gold standard’ assay sensitivity test. The necessity of careful placebo control is explained and the frequency of ECG assessments is considered. The central tendency and outlier analyses are discussed, together with the correct approaches to baseline adjustment.
The review concludes that the design and interpretation of TQTS must not be approached with mechanistic stereotypes, and highlights the importance of relating the QTc changes to drug plasma levels. |
doi_str_mv | 10.2165/11319160-000000000-00000 |
format | article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_745975204</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A221595458</galeid><sourcerecordid>A221595458</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-19cd53c474417a54cb2d498d80abbee49268fac2293334b54e88774cde7ff1ff3</originalsourceid><addsrcrecordid>eNqFkV9LwzAUxYMoOKdPfoGhiE-dvWnSJI9j-A8GIs7nkKbJ1tE1M2kf_PZmdJsogslDLsnvnHvDQWgE6RhDTu8AMhCQp0m6X311hAYATCQgCD5GgxSAJDSCp-gshFUEOM75AF3Ol867brEcvc5Hb21XViacoxOr6mAuducQvT_cz6dPyezl8Xk6mSWa5LSNzrqkmSaMEGCKEl3gkghe8lQVhTFExAZWaYxFlmWkoMRwzhjRpWHWgrXZEN32vhvvPjoTWrmugjZ1rRrjuiAZoYJRnJJIXv0iV67zTRxOYowZBs5xhK57aKFqI6vGutYrvbWUE4yBCkooj9T4Dyru0qwr7Rpjq3j_Q8B7gfYuBG-s3PhqrfynhFRuI5D7COQhgr6K0pvd2CpoVVuvGl2Fgx5nADnBLHKi50J8ahbGf3_v3x5fjb-Rbw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222721882</pqid></control><display><type>article</type><title>Thorough QT Studies: Questions and Quandaries</title><source>Springer Nature</source><creator>Malik, Marek ; Garnett, Christine E. ; Zhang, Joanne</creator><creatorcontrib>Malik, Marek ; Garnett, Christine E. ; Zhang, Joanne</creatorcontrib><description>The International Conference on Harmonisation E14 Guidance was successful in largely standardizing the conduct of the so-called thorough QT/QTc studies (TQTS). Nevertheless, there is still a spectrum of frequently encountered problems with details of design, conduct and interpretation of TQTS. Several of these challenges are reviewed here, starting with explaining that the TQTS goal is only to identify drugs for which the proarrhythmic risk might be considered excluded for the purposes of regulatory benefit-risk assessment. Suggestions are made on how to categorize and quantify or exclude proarrhythmic risk if the TQTS is positive. There is a conceptual need for TQTS, and this is discussed, together with reasons why restricted clinical registries cannot prove the absence of proarrhythmic liability of any drug.
Appropriate drug doses investigated in TQTS should be derived from the maximum clinically tolerable dose rather than from the known or expected therapeutic dose. With the help of concentration-QTc modelling, the standard therapeutic dose can be omitted from TQTS, especially if the study is expected to be negative. Conditions for single-dose TQTS acceptability are reviewed. The role of the so-called positive control is assessed, contrasting the role of a same-class comparator for the investigated drug. A single 400 mg dose of moxifloxacin is advocated as the present ‘gold standard’ assay sensitivity test. The necessity of careful placebo control is explained and the frequency of ECG assessments is considered. The central tendency and outlier analyses are discussed, together with the correct approaches to baseline adjustment.
The review concludes that the design and interpretation of TQTS must not be approached with mechanistic stereotypes, and highlights the importance of relating the QTc changes to drug plasma levels.</description><identifier>ISSN: 0114-5916</identifier><identifier>EISSN: 1179-1942</identifier><identifier>DOI: 10.2165/11319160-000000000-00000</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Biological and medical sciences ; Clinical trial. Drug monitoring ; Current Opinion ; Drug Safety and Pharmacovigilance ; Drug toxicity and drugs side effects treatment ; General pharmacology ; Mandatory drug testing ; Medical sciences ; Medicine ; Medicine & Public Health ; Methods ; Pharmaceutical industry ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Quality management ; Regulatory compliance ; Toxicity: cardiovascular system</subject><ispartof>Drug safety, 2010, Vol.33 (1), p.1-14</ispartof><rights>Adis Data Information BV 2010</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2010 Wolters Kluwer Health, Inc.</rights><rights>Copyright Wolters Kluwer Health Adis International Jan 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c465t-19cd53c474417a54cb2d498d80abbee49268fac2293334b54e88774cde7ff1ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23116427$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Malik, Marek</creatorcontrib><creatorcontrib>Garnett, Christine E.</creatorcontrib><creatorcontrib>Zhang, Joanne</creatorcontrib><title>Thorough QT Studies: Questions and Quandaries</title><title>Drug safety</title><addtitle>Drug-Safety</addtitle><description>The International Conference on Harmonisation E14 Guidance was successful in largely standardizing the conduct of the so-called thorough QT/QTc studies (TQTS). Nevertheless, there is still a spectrum of frequently encountered problems with details of design, conduct and interpretation of TQTS. Several of these challenges are reviewed here, starting with explaining that the TQTS goal is only to identify drugs for which the proarrhythmic risk might be considered excluded for the purposes of regulatory benefit-risk assessment. Suggestions are made on how to categorize and quantify or exclude proarrhythmic risk if the TQTS is positive. There is a conceptual need for TQTS, and this is discussed, together with reasons why restricted clinical registries cannot prove the absence of proarrhythmic liability of any drug.
Appropriate drug doses investigated in TQTS should be derived from the maximum clinically tolerable dose rather than from the known or expected therapeutic dose. With the help of concentration-QTc modelling, the standard therapeutic dose can be omitted from TQTS, especially if the study is expected to be negative. Conditions for single-dose TQTS acceptability are reviewed. The role of the so-called positive control is assessed, contrasting the role of a same-class comparator for the investigated drug. A single 400 mg dose of moxifloxacin is advocated as the present ‘gold standard’ assay sensitivity test. The necessity of careful placebo control is explained and the frequency of ECG assessments is considered. The central tendency and outlier analyses are discussed, together with the correct approaches to baseline adjustment.
The review concludes that the design and interpretation of TQTS must not be approached with mechanistic stereotypes, and highlights the importance of relating the QTc changes to drug plasma levels.</description><subject>Biological and medical sciences</subject><subject>Clinical trial. Drug monitoring</subject><subject>Current Opinion</subject><subject>Drug Safety and Pharmacovigilance</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>General pharmacology</subject><subject>Mandatory drug testing</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Methods</subject><subject>Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Quality management</subject><subject>Regulatory compliance</subject><subject>Toxicity: cardiovascular system</subject><issn>0114-5916</issn><issn>1179-1942</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNqFkV9LwzAUxYMoOKdPfoGhiE-dvWnSJI9j-A8GIs7nkKbJ1tE1M2kf_PZmdJsogslDLsnvnHvDQWgE6RhDTu8AMhCQp0m6X311hAYATCQgCD5GgxSAJDSCp-gshFUEOM75AF3Ol867brEcvc5Hb21XViacoxOr6mAuducQvT_cz6dPyezl8Xk6mSWa5LSNzrqkmSaMEGCKEl3gkghe8lQVhTFExAZWaYxFlmWkoMRwzhjRpWHWgrXZEN32vhvvPjoTWrmugjZ1rRrjuiAZoYJRnJJIXv0iV67zTRxOYowZBs5xhK57aKFqI6vGutYrvbWUE4yBCkooj9T4Dyru0qwr7Rpjq3j_Q8B7gfYuBG-s3PhqrfynhFRuI5D7COQhgr6K0pvd2CpoVVuvGl2Fgx5nADnBLHKi50J8ahbGf3_v3x5fjb-Rbw</recordid><startdate>2010</startdate><enddate>2010</enddate><creator>Malik, Marek</creator><creator>Garnett, Christine E.</creator><creator>Zhang, Joanne</creator><general>Springer International Publishing</general><general>Adis International</general><general>Wolters Kluwer Health, Inc</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7T2</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U2</scope></search><sort><creationdate>2010</creationdate><title>Thorough QT Studies</title><author>Malik, Marek ; Garnett, Christine E. ; Zhang, Joanne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-19cd53c474417a54cb2d498d80abbee49268fac2293334b54e88774cde7ff1ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Biological and medical sciences</topic><topic>Clinical trial. Drug monitoring</topic><topic>Current Opinion</topic><topic>Drug Safety and Pharmacovigilance</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>General pharmacology</topic><topic>Mandatory drug testing</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Methods</topic><topic>Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Quality management</topic><topic>Regulatory compliance</topic><topic>Toxicity: cardiovascular system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Malik, Marek</creatorcontrib><creatorcontrib>Garnett, Christine E.</creatorcontrib><creatorcontrib>Zhang, Joanne</creatorcontrib><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Safety Science and Risk</collection><jtitle>Drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malik, Marek</au><au>Garnett, Christine E.</au><au>Zhang, Joanne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thorough QT Studies: Questions and Quandaries</atitle><jtitle>Drug safety</jtitle><stitle>Drug-Safety</stitle><date>2010</date><risdate>2010</risdate><volume>33</volume><issue>1</issue><spage>1</spage><epage>14</epage><pages>1-14</pages><issn>0114-5916</issn><eissn>1179-1942</eissn><abstract>The International Conference on Harmonisation E14 Guidance was successful in largely standardizing the conduct of the so-called thorough QT/QTc studies (TQTS). Nevertheless, there is still a spectrum of frequently encountered problems with details of design, conduct and interpretation of TQTS. Several of these challenges are reviewed here, starting with explaining that the TQTS goal is only to identify drugs for which the proarrhythmic risk might be considered excluded for the purposes of regulatory benefit-risk assessment. Suggestions are made on how to categorize and quantify or exclude proarrhythmic risk if the TQTS is positive. There is a conceptual need for TQTS, and this is discussed, together with reasons why restricted clinical registries cannot prove the absence of proarrhythmic liability of any drug.
Appropriate drug doses investigated in TQTS should be derived from the maximum clinically tolerable dose rather than from the known or expected therapeutic dose. With the help of concentration-QTc modelling, the standard therapeutic dose can be omitted from TQTS, especially if the study is expected to be negative. Conditions for single-dose TQTS acceptability are reviewed. The role of the so-called positive control is assessed, contrasting the role of a same-class comparator for the investigated drug. A single 400 mg dose of moxifloxacin is advocated as the present ‘gold standard’ assay sensitivity test. The necessity of careful placebo control is explained and the frequency of ECG assessments is considered. The central tendency and outlier analyses are discussed, together with the correct approaches to baseline adjustment.
The review concludes that the design and interpretation of TQTS must not be approached with mechanistic stereotypes, and highlights the importance of relating the QTc changes to drug plasma levels.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><doi>10.2165/11319160-000000000-00000</doi><tpages>14</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0114-5916 |
ispartof | Drug safety, 2010, Vol.33 (1), p.1-14 |
issn | 0114-5916 1179-1942 |
language | eng |
recordid | cdi_proquest_miscellaneous_745975204 |
source | Springer Nature |
subjects | Biological and medical sciences Clinical trial. Drug monitoring Current Opinion Drug Safety and Pharmacovigilance Drug toxicity and drugs side effects treatment General pharmacology Mandatory drug testing Medical sciences Medicine Medicine & Public Health Methods Pharmaceutical industry Pharmacology. Drug treatments Pharmacology/Toxicology Quality management Regulatory compliance Toxicity: cardiovascular system |
title | Thorough QT Studies: Questions and Quandaries |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A44%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thorough%20QT%20Studies:%20Questions%20and%20Quandaries&rft.jtitle=Drug%20safety&rft.au=Malik,%20Marek&rft.date=2010&rft.volume=33&rft.issue=1&rft.spage=1&rft.epage=14&rft.pages=1-14&rft.issn=0114-5916&rft.eissn=1179-1942&rft_id=info:doi/10.2165/11319160-000000000-00000&rft_dat=%3Cgale_proqu%3EA221595458%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c465t-19cd53c474417a54cb2d498d80abbee49268fac2293334b54e88774cde7ff1ff3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=222721882&rft_id=info:pmid/&rft_galeid=A221595458&rfr_iscdi=true |